Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumeetinib (Haiyitan) plus osimertinib as first-line therapy in EGFR classic-mutant NSCLC with MET amplification or overexpression
CTR20251160Phase 3Active
- Sponsor
- Haihe
- Start
- Jun 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glumetinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Haihe. Started Jun 2025; status: active.
02
Drugs
glumetinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251160.